SCHEMBL3022967

SCHEMBL3022967

Cc1cc(C#N)cc(Oc2c(Br)ccc(CNC(=O)c3[nH]c(N)nc3Cl)c2F)c1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KCNH2 Q12809 1/20 0.34
XDH P47989 1/20 0.32
PKM P14618 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30
SCN9A Q15858 1/20 0.30
EPHX2 P34913 1/20 0.30
METTL3 Q86U44 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3029744 0.96 CYP3A4 (0.35) CYP3A4CYP2C9CYP2C19KCNH2PKM
SCHEMBL3036790 0.92 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19KCNH2EPHX2
SCHEMBL13982404 0.90 PRNP (0.32) CYP3A4CYP2C19
Trifluoroacetic Acid SCHEMBL3016666 0.88 CYP3A4 (0.39) CYP3A4CYP2C9CYP2C19KCNH2EPHX2
SCHEMBL3027504 0.86 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19KCNH2EPHX2
SCHEMBL3023375 0.86 CYP3A4 (0.45) CYP3A4CYP2C9CYP2C19KCNH2PKM
SCHEMBL3029925 0.85 CYP3A4 (0.43) CYP3A4CYP2C9CYP2C19SCN9AEPHX2
SCHEMBL3028240 0.85 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19KCNH2SCN9A
SCHEMBL3027058 0.84 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19KCNH2EPHX2
SCHEMBL3034593 0.84 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19KCNH2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US claimed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US claimed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP2C9 720/4885CYP2C19 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.